Treatment for multiple myeloma shows promiseBMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7398.1054-a (Published 15 May 2003) Cite this as: BMJ 2003;326:1054
- Janice Hopkins Tanne
- New York
Patients with multiple myeloma who were treated with high dose chemotherapy followed by stem cell rescue lived almost a year longer than patients who had standard treatment, a new study has found.
In the randomised controlled trial, 44% of patients in the intensive treatment group had a complete response to treatment, compared with only 8% in the standard treatment group (New England Journal of Medicine 2003;348:1875-83).
The study included 401 patients from 83 centres in the United Kingdom and New Zealand and took place between 1993 and 2000. Patients were previously untreated and were aged under 65 years.
Standard treatment (200 patients) was doxorubicin, carmustine, cyclophosphamide, and melphalan every six weeks until maximal response was attained. The number of cycles needed ranged …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial